🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. Ultomiris 1,100 mg/11 mL concentrate for solution for infusion, Anti C5 Complement mAb Placebo

    Alexion Europe SAS

    Delayed Graft Function after Kidney Transplantation

    phase 3 small molecule active

    1 trial

  2. Upadacitinib

    AbbVie

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  3. Upadacitinib

    AbbVie

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  4. Upadacitinib

    AbbVie

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  5. Upadacitinib

    AbbVie

    Spondyloarthritis

    phase 3 small molecule completed

    1 trial

  6. Upadacitinib

    AbbVie

    Crohn's Disease

    phase 3 small molecule active

    2 trials

  7. Upadacitinib

    AbbVie

    Atopic Dermatitis

    phase 3 small molecule active

    3 trials

  8. Upadacitinib (ABT-494)

    AbbVie

    Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  9. Upadacitinib Placebo, Upadacitinib

    AbbVie Deutschland GmbH & Co. KG

    non-segmental vitiligo

    phase 3 small molecule active

    1 trial

  10. Upadacitinib Placebo, Upadacitinib, Upadacitinib

    AbbVie Deutschland GmbH & Co. KG

    Alopecia Areata

    phase 3 small molecule active

    1 trial

  11. Upadacitinib, DUPILUMAB, Upadacitinib, Upadacitinib, Upadacitinib, Upadacitinib, DUPILUMAB

    AbbVie Deutschland GmbH & Co. KG

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  12. Upadacitinib, Placebo for upadacitinib tablet, Upadacitinib, Upadacitinib

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  13. Upadacitinib, RoActemra 162 mg solution for injection in pre-filled syringe., RoActemra 162 mg solution for injection in pre-filled pen., Upadacitinib, RoActemra 20 mg/mL concentrate for solution for infusion

    AbbVie Deutschland GmbH & Co. KG

    juvenile idiopathic arthritis

    phase 3 small molecule active

    1 trial

  14. Ustekinumab

    The First People's Hospital of Lianyungang

    Crohn Disease

    phase 3 small molecule active

    1 trial

  15. Ustekinumab Dose Based on BSA and Body Weight

    Janssen Cilag International NV

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial

  16. VALACICLOVIR ARROW 500 mg, comprimé pelliculé sécable, PREVYMIS PLACEBO, VALACICLOVIR PLACEBO, PREVYMIS 240 mg film-coated tablets

    Pari Pharma GmbH

    Diseases [C] - Virus Diseases [C02]

    phase 3 small molecule active

    1 trial

  17. VEGF Trap-Eye (BAY86-5321)

    Regeneron UK Limited

    Diabetes Mellitus

    phase 3 mab completed

    1 trial

  18. VELCADE 3.5 mg powder for solution for injection, Cyclophosphamide Tablets 50 mg, JNJ-54767414, Dexamethason 4 mg JENAPHARM®

    Janssen-Cilag International N.V.

    AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis)

    phase 3 small molecule active

    1 trial

  19. VENETOCLAX, AZACITIDINE, VENETOCLAX, CYTARABINE, Ziftomenib, CYTARABINE, VENETOCLAX, Ziftomenib Placebo, Daunoblastin® 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung

    Kura Oncology

    NPM1-m and KMT2A-r Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  20. VENETOCLAX, RITUXIMAB, PIRTOBRUTINIB, PIRTOBRUTINIB, VENETOCLAX

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)

    phase 3 small molecule active

    1 trial

  21. VENETOCLAX, VENETOCLAX, BENDAMUSTINE, ACALABRUTINIB, CYCLOPHOSPHAMIDE, OBINUTUZUMAB, VENETOCLAX, FLUDARABINE, RITUXIMAB

    Lacuna Pharma Pty Ltd

    Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation

    phase 3 small molecule active

    1 trial

  22. VINCRISTINE SULFATE, RITUXIMAB, RITUXIMAB, APIXABAN, Golcadomide, PREDNISONE, DOXORUBICIN HYDROCHLORIDE, CYCLOPHOSPHAMIDE MONOHYDRATE, Golcadomide, Golcadomide 0.2 mg capsule, Golcadomide 0.3 mg capsule, Golcadomide 0.4 mg capsule, Golcadomide, Neulasta 6 mg solution for injection, PREDNISOLONE , VINCRISTINE SULFATE

    Celgene Europe Limited

    High-risk Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  23. VIR-7831 (sotrovimab)

    Vir Biotechnology

    Covid19

    phase 3 mab completed

    1 trial

  24. VISIPAQUE 320 mg d’I/mL, solution injectable, LIPIODOL ULTRA FLUIDE 480 mg/ml, solution injectable, HEPARINE CHOAY 5 000 UI/1 ml, solution injectable, XYLOCAINE 5 mg/ml SANS CONSERVATEUR, solution injectable, Optiray 300 (300 mg I/mL), solution injectable en flacon

    Pari Pharma GmbH

    Knee OsteoArthritis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources